Compare PDM & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDM | CRON |
|---|---|---|
| Founded | 1997 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Building operators | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 1997 | 2015 |
| Metric | PDM | CRON |
|---|---|---|
| Price | $7.62 | $2.70 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | 864.3K | ★ 1.3M |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,994,000.00 | $117,615,000.00 |
| Revenue This Year | $0.91 | $18.81 |
| Revenue Next Year | $3.24 | $34.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 34.82 |
| 52 Week Low | $5.46 | $1.60 |
| 52 Week High | $9.19 | $3.43 |
| Indicator | PDM | CRON |
|---|---|---|
| Relative Strength Index (RSI) | 34.15 | 52.60 |
| Support Level | $7.17 | $2.44 |
| Resistance Level | $7.83 | $2.77 |
| Average True Range (ATR) | 0.37 | 0.08 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 1.41 | 62.50 |
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.